Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

RAXIBACUMAB Drug Profile

See Plans and Pricing

« Back to Dashboard

Summary for Tradename: RAXIBACUMAB

Patents:	7
Applicants:	1
BLAs:	1
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for RAXIBACUMAB

Recent Clinical Trials for RAXIBACUMAB

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
GlaxoSmithKline	Phase 4
GlaxoSmithKline	Phase 3
Human Genome Sciences Inc., a GSK Company	Phase 3

See all RAXIBACUMAB clinical trials

Pharmacology for RAXIBACUMAB

Mechanism of Action	Anthrax Protective Antigen-directed Antibody Interactions

Patent Text Search: US Patents for RAXIBACUMAB

These patents were identified by searching patent claims

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Human Genome Sciences Inc.	RAXIBACUMAB	raxibacumab	INJECTABLE; IV (INFUSION)	125349	001	2012-12-14	Start Trial	CureVac AG (Tubingen, DE)	2032-02-15	RX		search
Human Genome Sciences Inc.	RAXIBACUMAB	raxibacumab	INJECTABLE; IV (INFUSION)	125349	001	2012-12-14	Start Trial	Aegis Therapeutics LLC (San Diego, CA)	2026-06-23	RX		search
Human Genome Sciences Inc.	RAXIBACUMAB	raxibacumab	INJECTABLE; IV (INFUSION)	125349	001	2012-12-14	Start Trial	Aegis Therapeutics, LLC (San Diego, CA)	2026-06-23	RX		search
Human Genome Sciences Inc.	RAXIBACUMAB	raxibacumab	INJECTABLE; IV (INFUSION)	125349	001	2012-12-14	Start Trial	SynChem, Inc. (Elk Grove Village, IL)	2032-05-31	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patents for RAXIBACUMAB

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Japan	2015508646	Start Trial
India	5670DEN2014	Start Trial
European Patent Office	2814963	Start Trial
Singapore	11201403944R	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter

McKinsey

Boehringer Ingelheim

Mallinckrodt

Moodys

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.